What are the recent financial highlights of LAURUS LABS LIMITED?

LAURUS LABS LIMITED recently reported a total revenue of ₹5,273.33 Cr and a net profit margin of 3.8%. These metrics reflect the company’s consistent financial performance.

What is the dividend yield of LAURUS LABS LIMITED?

LAURUS LABS LIMITED offers a dividend yield of 0.14%, with a dividend rate of ₹0.8 per share.

What are the key financial metrics of LAURUS LABS LIMITED?

Key financial metrics include a trailing P/E ratio of 147.98927, forward P/E of 23.620026, book value of ₹77.095, price-to-book ratio of 7.1599975, and a market capitalization of ₹297.67 billion.

What does LAURUS LABS LIMITED do?

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Loading...

₹ 0 0.00%

Loading... BSE: Loding... NSE: Lauruslabs

About

Loading... ^[1]

Website BSE NSE

Market Cap ₹ 0 Cr.
Current Price ₹ 0
High / Low ₹ 0 / 0
Stock P/E
Dividend Yield 0 %
ROE 0 %
EPS 0
P/B Ratio 0
Net Profit Margin 0 %
Debt to Equity 0
ROCE 0 %
Interest Coverage 0 %

Stock News - Lauruslabs

Latest updates related to Lauruslabs

Sr No.	Title	Sentiment
1	Institutions profited after Laurus Labs Limited's (NSE:LAURUSLABS) market cap rose ₹16b last week but retail investors profited the most Simply Wall St	🔄
2	LAURUSLABS Outlook for the Week (March 10, 2025 – March 14, 2025) EquityPandit	🔄
3	Laurus Labs' (NSE:LAURUSLABS) five-year total shareholder returns outpace the underlying earnings growth Simply Wall St	🔄
4	#LaurusLabs to invest ₹833 crore in JV with Slovenian firm linkedin	🔄

Peer Comparison

Macro Industry: Loading.. | Sector: Loading.. | Industry: Loading.. | Basic Industry: Loading..

Loading peers table...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Loading data...

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Loading Profit & Loss data...

Compounded Sales Growth
10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth
10 Years:
5 Years:
3 Years:
TTM:

Stock Price CAGR
10 Years:
5 Years:
3 Years:
1 Year:

Return on Equity
10 Years:
5 Years:
3 Years:
Last Year:

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Shareholding Pattern

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Delivery Data

Insider Data

Technical Data

Static Application Security Testing

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls

Explore More Stocks

SHAHALLOYS GULFOILLUB CHEMCON GALAPREC FIRSTCRY RTNINDIA AMRUTANJAN EIEL JSFB PTL